- Home
- About Us
- Facilities
- Management
- Scientific Advisory Team
- Business Advisory Team
- Technology
- Product Development
- Business Development
- Contact Us
About
Us
CaPtivate Pharmaceuticals
is a development-stage biotechnology company focused on developing improved
vaccines and vaccine delivery systems through its proprietary calcium phosphate
(CaP) nanoparticle adjuvant
technology. CaP nanoparticle
adjuvant has been proven safe and effective for delivery of vaccines by injection
or via mucosal administration. The Company's technology has successfully
completed a single dose pre-clinical toxicity study for the administration of CaP orally, into muscles, under the skin, and into the
lungs. The technology has originally been developed by BioSante Pharmaceuticals, Inc. In 2011, BioSante
spun out its CaP nanotechnology into CaPtivate Pharmaceuticals, and granted CaPtivate
an exclusive license to develop and commercialize calcium phosphate products. BioSante retains a minority ownership position in CaPtivate and continues to support CaPtivate
in its development efforts. Through IP agreements with BioSante,
CaPtivate is also assigned entire rights and interest
in the 2007 license agreement of CaP nanotechnology
to Medical Aesthetics Technology Corporation (MATC)
in the field of aesthetic medicine.
Phone: 215-589-6359 |
Fax: 215-589-6324 |
Email: info@captivatepharma.com
Pennsylvania Biotechnology Center 3805 Old Easton Road, Doylestown, PA 18902-8400 US
